Revance Therapeutics, Inc. Is A Biotechnology Company Based In Nashville, Tennessee, Focused On Developing, Manufacturing, And Commercializing Neuromodulators And Aesthetic Products For Therapeutic And Cosmetic Applications. Founded In 1999, Revance Operates In Over 60 Countries And Became A Subsidiary Of Crown Laboratories, Inc. In February 2025. The Company Employs Around 597 People And Has Reported Revenues Exceeding $250 Million In Recent Years. Revance's Flagship Product Is *daxxify*, A Botulinum Toxin Injection Approved For Treating Glabellar Lines And Cervical Dystonia, With Additional Clinical Trials For Other Indications. The Company Also Offers The *resilient Hyaluronic Acid (rha)* Collection Of Dermal Fillers, Designed To Address Dynamic Facial Wrinkles. Through Crown Laboratories, Revance Markets Consumer Skincare Products And Devices, Including *skinpen Precision* And *biojuve*. Revance Primarily Serves Healthcare Providers In Aesthetic Medicine And Therapeutic Treatments, As Well As Consumers Seeking Skincare Solutions.